Clinical trial · Interventional
Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma
NCT00314873CI-TRIAL-00014766completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is important to demonstrate if single agent activity is noted for patients with thymic tumors over expressing c-kit and/or PDGF. If this current trial is positive, it opens the door to evaluate other combination of drugs with imatinib in thymic tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thymic Carcinoma | Thymus Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gleevec (imatinib) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- To determine the objective response rate of imatinib in patients with c-kit or PDGF positive thymic carcinoma.
- timeFrame
- baseline through progression
- measure
- To determine the duration of remission of patients with thymic carcinoma treated with imatinib.
- timeFrame
- baseline through progression
- measure
- To determine the toxicity of imatinib in this patient population.
- timeFrame
- baseline through end of study
- measure
- To determine the incidence of kit mutations in thymic malignancies.
- timeFrame
- baseline
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histological or cytological proof of advanced C-KIT positive or PDGFR positive thymic carcinoma. For protocol purposes, advanced disease is defined as disease * Patient must have at least one documented measurable lesion obtained by imaging within 28 days prior to being registered for protocol therapy. * No prior imatinib therapy. * Age \> 18 years at the time of consent * ECOG performance status of 0 or 1 * ANC ≥ 1500/mm3,Platelet count ≥ 100,000/mm,Total bilirubin \< 1.5ULN,3.10 Serum creatinine ≤ 1.7 mg/dl,ALT and AST ≤ 3 x ULN Exclusion Criteria: * Clinically significant infections as judged by the treating investigator * Clinically significant concurrent illnesses * Females of childbearing potential not using birth control or breastfeeding * Prior radiation therapy \> 25% of the bone marrow * Symptomatic brain metastasis * History of Grade III/IV cardiac problems * History of major surgery within 14 days prior to being registered * Treatment with any investigational agent within 30 days prior to being registered for protocol therapy.
References
Publications (0)
Data not yet available
No reference posted for this study.